NFKB1 and gastric cancer: TPL could inactivate CAFs and sensitized GC cells to SN38 through hampering NF-κB signal pathway in both CAFs (Fig. 3e) and GC cells (Fig. 4i), suggesting its potential antitumor efficacy in advanced GC combination therapy.